24 reports

  • May 12, 2017: Otonomy Announces OTIPRIO Data Presentation and Symposium at the American Society of Pediatric Otolaryngology Annual Meeting
  • Nov 05, 2018: Otonomy reports third quarter 2018 financial results and provides corporate update

Presented Results from OTIVIDEX AVERTS-## Trial at International Otolaryngology Conference: In September 2018, Mr.

  • Ear, Nose, And Throat Medicine
  • United States
  • Company
  • Company Financials
  • Otonomy, Inc.
  • JAN 24, 2018: SENSORION ANNOUNCES MULTIPLE POSTER PRESENTATIONS AT THE ARO 2018 MIDWINTER MEETING
  • APR 23, 2018: FIRST POTENTIAL BIOMARKER FOR NOISE-INDUCED HEARING LOSS IDENTIFIED

The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are ##, ##, ## and ## respectively.

  • Ear Disease
  • Ear, Nose, And Throat Medicine
  • World
  • Product Initiative
  • Sensorion S.A.

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ##, ## and ## respectively.

  • Ear Disease
  • Ear, Nose, And Throat Medicine
  • Molecular Diagnostics
  • Therapy
  • Sensorion S.A.
  • Sep 24, 2015: Otonomy to Present Results for OTO-104 Phase 2b Clinical Trials at 2015 AAO-HNSF Annual Meeting
  • Jun 20, 2017: Otonomy to Host Key Opinion Leader Meeting for Investors on Meniere's Disease

Following the lead-in period, eligible subjects will be randomized ##:## to a single intratympanic injection of ## mg OTO-## or placebo (gel vehicle).

  • Ear, Nose, And Throat Medicine
  • Pharmaceutical
  • United States
  • Product Initiative
  • Otonomy, Inc.
  • Dec 28, 2017: Auris Medical to Provide Update on Its AM-111 Hearing Loss Program on Thursday, January 4, 2018
  • OTHER LOCATIONS & SUBSIDIARIES

The securities are being offered in a unit comprised of one share, one Series A warrant to purchase ##. ## of a share and one Series B warrant to purchase ##. ## of a share.

  • Ear Disease
  • Ear, Nose, And Throat Medicine
  • United States
  • Company Financials
  • Auris Medical Holding AG
  • Sep 24, 2015: Otonomy to Present Results for OTO-104 Phase 2b Clinical Trials at 2015 AAO-HNSF Annual Meeting
  • from baseline to Month 3 in the OTIVIDEX group vs. 40% for placebo.

Following an initial one month lead-in period, eligible subjects were randomized ##:## to a single intratympanic injection of OTIVIDEX or placebo.

  • Ear, Nose, And Throat Medicine
  • Pharmaceutical
  • United States
  • Product Initiative
  • Otonomy, Inc.

According to the American Academy of Otolaryngology, the total cost of a cochlear implant, including everything from evaluation to rehabilitation, can be as much as $##, ##.

  • Ear, Nose, And Throat Medicine
  • Health Services
  • Carl Zeiss AG
  • Danaher Corporation
  • Olympus Corporation

ACCORDING TO THE AMERICAN ACADEMY OF OTOLARYNGOLOGY, THE TOTAL COST OF A COCHLEAR IMPLANT, INCLUDING EVERYTHING FROM EVALUATION TO REHABILITATION CAN COST AS MUCH AS $##, ##.

  • Ear, Nose, And Throat Medicine
  • World
  • Medtronic, Inc.
  • Olympus Corporation
  • Smith & Nephew Plc
  • Aug 03, 2017: Otonomy Reports Second Quarter 2017 Financial Results and Provides Corporate Update
  • May 09, 2018: Otonomy Reports First Quarter 2018 Financial Results and Provides Corporate Update

Lambert, M. D., Professor and Chair, Department of Otolaryngology-Head & Neck Surgery, Medical University of South Carolina, and Anthony A.

  • Ear, Nose, And Throat Medicine
  • United States
  • Company
  • Company Financials
  • Otonomy, Inc.
  • PATHWAY WITH THE FDA AND EMA IN THE SECOND QUARTER OF 2018. THE DATA WILL ALSO BE SUBMITTED FOR PEER REVIEW PUBLICATION AND PRESENTATION AT A MEDICAL MEETING IN 2018.
  • Nov 28, 2017: Auris Medical Reports Top-Line Results from Phase 3 Trial of AM-111 in Sudden Deafness

Patients were randomized to receive AM- ## ##. ## mg/ mL, ##. ## mg/ mL or placebo in a ##:##:## ratio.

  • Ear, Nose, And Throat Medicine
  • Health Services
  • United States
  • World
  • Product Initiative

Audigy is a preeminent US based provider of business and performance management solutions to independent hearing care, otolaryngology, otology and neurotology practices and leading University programs in North America.

  • Ear, Nose, And Throat Medicine
  • World
  • Demand
  • Cochlear Limited
  • Sonova Holding AG

You can easily book an appointment with one online.

  • Ear, Nose, And Throat Medicine
  • World
  • Forecast
  • Natus Medical Incorporated
  • William Demant
  • Apr 12, 2018: Sensorion reports full year 2017 results

More than one third of all adults suffer from one form or another of vestibular disorders.

  • Ear Disease
  • Ear, Nose, And Throat Medicine
  • Pharmaceutical
  • France
  • Sensorion S.A.
  • May 04, 2015: Auris Medical Provides Update on Clinical Development Plan for AM-111

The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ##, ## and ## respectively.

  • Ear Disease
  • Ear, Nose, And Throat Medicine
  • World
  • Product Initiative
  • Auris Medical Holding AG
  • 5.2.3 BY REGION
  • is enabling people to purchase the technologically

Q. ##.

  • Ear, Nose, And Throat Medicine
  • North America
  • United States
  • World
  • Market Size
  • Mar 04, 2011: Auris Medical's AM-111 Protects Against Hearing Loss From Cochlear Implant Electrode Insertion Trauma
  • Nov 28, 2017: Auris Medical Reports Top-Line Results from Phase 3 Trial of AM-111 in Sudden Deafness

Patients were randomized to receive AM- ## ##. ## mg/ mL, ##. ## mg/ mL or placebo in a ##:##:## ratio.

  • Ear Disease
  • Ear, Nose, And Throat Medicine
  • Therapy
  • United States
  • Product Initiative
  • 8.4.3 RECENT DEVELOPMENTS

Audigy is a preeminent US based provider of business and performance management solutions to independent hearing care, otolaryngology, otology and neurotology practices and leading University programs in North America.

  • Ear, Nose, And Throat Medicine
  • World
  • Cochlear Limited
  • RION Co., Ltd
  • Sonova Holding AG
  • 5. All the trials included are unique trials.

Boehringer Sohn AG & Co KG ## ## ## ## ## ## ## Sanofi ## ## ## ## ## ## ## Astellas Pharma Inc ## ## ## ## ## ## ## E.

  • Clinical Trial
  • Ear, Nose, And Throat Medicine
  • Monoclonal Antibody
  • World
  • Bristol-Myers Squibb Company
  • 4.1 BIBLIOGRAPHY

ET AL. (2011) ' HEAD AND NECK CANCER-PART ##: EPIDEMIOLOGY, PRESENTATION, AND PRESERVATION', CLINICAL OTOLARYNGOLOGY, ##(##), PP. ##-##.

  • Cancer
  • Ear, Nose, And Throat Medicine
  • Japan
  • United States
  • Forecast

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Clinical Trial
  • Ear, Nose, And Throat Medicine
  • Monoclonal Antibody
  • United States
  • World
  • Apr 20, 2012
  • FEATURED NEWS & PRESS RELEASES

KG ## ## ## ## ## ## Orbis Biosciences, Inc. ## ## ## ## ## ## Otologic Pharmaceutics, Inc. ## ## ## ## ## ## Xigen SA ## ## ## ## ## ## Total ## ## ## ## ## ## Source: Global Markets Direct Company Name Phase III Phase II Phase I

  • Ear, Nose, And Throat Medicine
  • United States
  • World
  • Company Operations
  • Product Initiative
  • 9.2 References

American Academy of Otolaryngology.

  • Cancer
  • Ear, Nose, And Throat Medicine
  • Health Services
  • Healthcare
  • Therapy

Head and neck cancer

4385 5000 3900
  • Epidemiologist Insight

Otolaryngology - Head and Neck Surgery, ##(##), ##-## < DOI> ##. ##/ j. otohns. 2006. ##. ##< / DOI>. de Souza DLB, Bernal Pérez MM, Curado MP (2011) Predicted incidence of oral cavity, oropharyngeal, laryngeal, and hypopharyngeal cancer in Spain and implications for cance

  • Ear, Nose, And Throat Medicine
  • United States
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Eli Lilly & Co.
  • is a representative pipeline of the nanoparticles under review in research
  • NANOPARTICLES FOR INNER EAR DISEASES: RESEARCH PIPELINE AT UNIVERSITIES

CHAPTER OUTLINES ##. ##.

  • Ear, Nose, And Throat Medicine
  • United States
  • AudioCure Pharma GmbH
  • Autifony Therapeutics Limited
  • Cochlear Limited